Michael Har-Noy

1
Michael Har-Noy
Founder and CEO of Immunovative Therapies, Ltd
2
Studying AlloStimTM Along With Chaperone Rich
Protein Lysate
Dr. Michael Har-Noy, founder and CEO of
Immunovative Therapies, Ltd., says that the power
of the human immune system can be successfully
harnessed to kill malignant tumors and to prevent
their recurrence. Dr. Michael Har-Noy says that
preliminary data indicates that AlloStimTM, his
companys lead product, has powerful anti-tumor
activity against a wide range of malignancies.
Dr. Michael Har-Noy is now conducting a Phase
I/II trial that combine AlloStimTM with Chaperone
Rich Protein Lysate (CRCL). He hopes this
combination will both eradicate malignant tumors
and prevent their recurrence. More information
about Dr. Michael Har-Noys landmark phase I/II
trial of CRCL-AlloVaxTM can be found at
www.immunocare.net.
3
Compassionate Use Program Is Underway In Bangkok,
Thailand
Dr. Michael Har-Noy, Immunovative Therapies
Ltd.s CEO and founder, says that patients with
metastatic cancer that have exhausted all
conventional treatment options may qualify for
treatment using his companys unique biologic
products. Dr. Michael Har-Noy indicates that his
Compassionate Use program in Bangkok, Thailand is
being conducted along with a phase I/II trial of
CRCL-AlloVaxTM, one of his companys leading
drugs. Dr. Michael Har-Noy is also testing the
drug AlloStimTM in HIV positive patients.
Interested parties should visit the website,
www.immunocare.net, for more information.
4
Proprietary Drugs May Be Effective Against Many
Different Cancers
Preliminary data show that AlloStimTM and
CRCL-AlloVaxTM, two proprietary compounds
developed by Dr. Michael Har-Noy, have activity
against a wide variety of malignancies. Dr.
Michael Har-Noy, founder and CEO of Immunovative
Therapies Ltd., a biotechnology company in
Israel, says that he is planning phase I/II
trials of AlloStimTM in hepatocellular carcinoma
and in head and neck malignancies. Dr. Michael
Har-Noy is also designing phase II/III marketing
trials for his drugs in patients with HER2
breast cancer and KRAS gene positive colon
cancer. Please visit www.immunocare.net for more
information.
5
http//michaelhar-noy.brandyourself.com/